PH12020551343A1 - 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer - Google Patents

7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Info

Publication number
PH12020551343A1
PH12020551343A1 PH12020551343A PH12020551343A PH12020551343A1 PH 12020551343 A1 PH12020551343 A1 PH 12020551343A1 PH 12020551343 A PH12020551343 A PH 12020551343A PH 12020551343 A PH12020551343 A PH 12020551343A PH 12020551343 A1 PH12020551343 A1 PH 12020551343A1
Authority
PH
Philippines
Prior art keywords
prophylaxis
treatment
liver cancer
derivatives
compounds
Prior art date
Application number
PH12020551343A
Inventor
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Sabine Hoves
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH12020551343A1 publication Critical patent/PH12020551343A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.
PH12020551343A 2018-02-28 2020-08-27 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer PH12020551343A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28
PCT/EP2019/054729 WO2019166432A1 (en) 2018-02-28 2019-02-26 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Publications (1)

Publication Number Publication Date
PH12020551343A1 true PH12020551343A1 (en) 2021-06-21

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020551343A PH12020551343A1 (en) 2018-02-28 2020-08-27 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer

Country Status (19)

Country Link
EP (1) EP3758707A1 (en)
JP (1) JP7089596B2 (en)
KR (1) KR20200128414A (en)
CN (1) CN111801100B (en)
AR (1) AR114419A1 (en)
AU (1) AU2019228654A1 (en)
BR (1) BR112020016509A2 (en)
CA (1) CA3091950A1 (en)
CL (1) CL2020002139A1 (en)
CO (1) CO2020010306A2 (en)
IL (1) IL276817A (en)
MA (1) MA52412A (en)
MX (1) MX2020008746A (en)
PE (1) PE20211456A1 (en)
PH (1) PH12020551343A1 (en)
RU (1) RU2020131012A (en)
SG (1) SG11202008291XA (en)
TW (1) TW202003518A (en)
WO (1) WO2019166432A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (en) 2016-08-29 2019-01-30 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
KR102409595B1 (en) 2020-06-29 2022-06-17 한국과학기술연구원 Novel purinone derivatives as protein kinase CSF-1R inhibitor
CN112420196A (en) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 Prediction method and system for survival rate of acute myocardial infarction patient within 5 years
WO2024013205A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (en) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 Heterocyclic compounds
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
SG175796A1 (en) * 2009-05-21 2011-12-29 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
EP2491035B1 (en) * 2009-10-22 2017-08-30 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
JP5848761B2 (en) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Prodrugs of NH acidic compounds: derivatives of esters, carbonates, carbamates and phosphonates
BR112013002940A2 (en) * 2010-08-13 2019-09-24 Baylor Res Institute new vaccine adjuvants based on targeting adjuvants for antibodies directly to antigen presenting cells
DK3294740T3 (en) * 2015-05-08 2019-11-04 H Hoffmann La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
SI3504210T1 (en) 2016-08-29 2021-08-31 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
AU2017326400B2 (en) * 2016-09-13 2023-03-30 F. Hoffmann-La Roche Ag Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor

Also Published As

Publication number Publication date
BR112020016509A2 (en) 2020-12-15
RU2020131012A (en) 2022-03-28
CN111801100A (en) 2020-10-20
JP2021514972A (en) 2021-06-17
TW202003518A (en) 2020-01-16
PE20211456A1 (en) 2021-08-05
EP3758707A1 (en) 2021-01-06
MA52412A (en) 2021-06-02
WO2019166432A1 (en) 2019-09-06
AR114419A1 (en) 2020-09-02
KR20200128414A (en) 2020-11-12
AU2019228654A1 (en) 2020-09-03
CL2020002139A1 (en) 2021-01-04
SG11202008291XA (en) 2020-09-29
MX2020008746A (en) 2020-09-28
CO2020010306A2 (en) 2020-08-31
JP7089596B2 (en) 2022-06-22
IL276817A (en) 2020-10-29
CN111801100B (en) 2023-10-24
CA3091950A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
MX2023001876A (en) Rapamycin derivatives.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2016017030A (en) Mnk inhibitors and methods related thereto.
PH12019500432A1 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
EA201650031A1 (en) DERIVATIVES PYRROLIDIN-2,5-DIONA, PHARMACEUTICAL COMPOSITIONS AND METHODS OF APPLICATION AS IDO1 INHIBITORS
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021014531A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2022005298A (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
NZ735249A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease
PH12016502281A1 (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
EA201892188A1 (en) PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
MA39993A (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors